Quick Answer
Boundless Bio, Inc. reported Diluted EPS of $2.60 per share (loss) for fiscal year 2025.
Boundless Bio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.60 | +32.5% |
| 2024 | -$3.85 | +90.5% |
| 2023 | -$40.65 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.62 | +16.2% | +11.4% |
| June 30, 2025 | -$0.70 | +9.1% | +1.4% |
| March 31, 2025 | -$0.71 | +94.2% | +4.1% |
| September 30, 2024 | -$0.74 | +93.1% | +3.9% |
| June 30, 2024 | -$0.77 | +92.5% | +93.7% |
| March 31, 2024 | -$12.27 | -23.8% | -14.6% |
| September 30, 2023 | -$10.71 | — | -4.2% |
| June 30, 2023 | -$10.28 | — | -3.7% |
- Boundless Bio, Inc. showed an increase of +32.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Boundless Bio, Inc.’s diluted eps has grown by 93.6% (from $40.65 per share (loss) to $2.60 per share (loss)).
- The most recent figure is from Boundless Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: